Experimental drug ecopipam shows 30% tic reduction in Tourette syndrome trials

Children and teens with Tourette syndrome experience repetitive, difficult-to-control motor and vocal tics that impact daily functioning, with current treatments often avoided due to severe side effects.

For children whose bodies betray them with uncontrollable movements and sounds, the search for relief has long meant choosing between suffering the condition or enduring the heavy toll of its treatments. A clinical trial presented in Seattle now suggests that ecopipam — a drug that once sought a different purpose — may offer young Tourette patients meaningful relief from tics without the weight gain and mood disruptions that have made existing medications a last resort for so many families. The finding does not close the chapter on this neurological condition, but it may open a door that has b

Experimental drug ecopipam shows 30% tic reduction in Tourette syndrome trials

Cobertura Relacionada

Recibe The Register en tu bandeja